U.S. RESEARCH ROUNDUP- Arcutis Biotherapeutics, Artiva Biotherapeutics, Nuvalent

Arcutis Biotherapeutics

30/12/2024 11:40

Dec 30 (Reuters) - Wall Street securities analysts revised their ratings and price
targets on several U.S.-listed companies, including Arcutis Biotherapeutics, Artiva
Biotherapeutics and Nuvalent on Monday. 
    
  HIGHLIGHTS        
    
                 * Arcutis Biotherapeutics  ARQT.O : H.C. Wainwright initiates coverage with buy
 rating
 
                 * Artiva Biotherapeutics  ARTV.O : H.C. Wainwright initiates coverage with buy
 rating 
 
                 * Nuvalent Inc  NUVL.O : H.C. Wainwright initiates coverage with buy rating and PT
 $110
 
                
Following is a summary of research actions on U.S. companies reported by Reuters on Monday.
Stock entries are in alphabetical order
    
                 * Arcutis Biotherapeutics  ARQT.O : H.C. Wainwright initiates coverage with buy rating
 
                 * Artiva Biotherapeutics  ARTV.O : H.C. Wainwright initiates coverage with buy rating 
 
                 * BigBear.ai Holdings Inc  BBAI.N : H.C. Wainwright raises PT to $7 from $3
 
                 * Boston Scientific Corp  BSX.N : BTIG raises target price to $101 from $97 
 
                 * Emergent Biosolutions  EBS.N : H.C. Wainwright initiates coverage with buy rating; PT $15
 
                 * Exelixis Inc  EXEL.O : RBC raises target price to $38 from $34
 
                 * Insulet Corp  PODD.O : BTIG raises target price to $300 from $270
 
                 * Metavia Inc  MTVA.O : H.C. Wainwright initiates coverage with buy rating; PT $12
 
                 * Nuvalent Inc  NUVL.O : H.C. Wainwright initiates coverage with buy rating and PT $110
 
 
 (Compiled by Bengaluru Newsroom)
 ((Diaries@thomsonreuters.com))